literature.cafe

518 readers
14 users here now
(and anyone else, really)

This is a general special interest lemmy instance focusing on lovers of all things pertaining to reading and writing and all of the people that enjoy it as well as fandoms and niches that exist within reading circles. We federate with other instances, with our local communities being focused primarily on the above.

If you want to federate a new community, go to lemmyverse.net and copy a link to a community and paste it into the search bar. Be patient!

Also, consider installing instance assistant to better navigate lemmy and find communities better! Find links to download them here: firefox, chrome, edge


Instance Rules
  1. Keep it cozy. (No -isms, bigotry, gatekeeping, or general disrespect. Just be nice!)
  2. Please, no visual porn. (Smut and discussion of smut is OK as long as it is tagged as NSFW.)
  3. No spam.
  4. Be mindful of other instance rules.
  5. Keep self-promo to a minimum.
  6. Tag AI generated content as such.
  7. Please avoid piracy.

Server Info

Registration is open with human approval, just to make sure there's no bots afoot. Approval should take less than a day (and are sometimes near instant)

Please check your spam folder for an email from noreply@literature.cafe if you are having difficulty finding email confirmation.

Community creation is enabled. When creating new communities please be mindful of the instance focus.

If you have any issues or concerns, please message an admin

Fediseer Guarantees


For those visiting from other instances, we have a community directory to make finding communities easier: !411@literature.cafe


We also have alternative lemmy UIs to use for those who want them.

A familiar UI - old.literature.cafe

Photon - ph.literature.cafe

Tesseract (photon fork with more multimedia focused features) - t.literature.cafe


Donations are greatly appreciated and go entirely to server costs but are not required.

List of Patrons Daily Uptime Ratio Weekly Uptime Ratio Average Response Time

founded 1 year ago
ADMINS
1
 
 

Adding Moderna’s in-development cancer vaccine to a standard treatment for melanoma dramatically reduces cancer survivors’ risk of death or recurrence, according to newly shared trial data.

Moderna and pharma giant Merck are developing an mRNA-based cancer vaccine, mRNA-4157 (V940), for people who’ve had high-risk melanomas removed.

The vaccine works by instructing the body to make up to 34 “neoantigens.” These are proteins found only on the cancer cells, and Moderna personalizes the vaccine for each recipient so that it carries instructions for the neoantigens on their cancer cells.

The idea behind the vaccine is that, by prompting the body to make these proteins, it can prepare the immune system to quickly identify and attack any new cancer cells bearing them, preventing recurrence.

What’s new? In the ongoing phase 2b KEYNOTE-942 study, Moderna and Merck are comparing the cancer vaccine’s ability to prevent melanoma recurrence or death when combined with Keytruda, Merck’s FDA-approved cancer treatment, to Keytruda alone.

2
3
4
 
 

There is a discussion on Hacker News, but feel free to comment here as well.

view more: next ›